SOURCE: Medical Nutrition USA, Inc.

January 16, 2008 08:30 ET

Medical Nutrition USA Receives Wound Care Patent

ENGLEWOOD, NJ--(Marketwire - January 16, 2008) - Medical Nutrition USA, Inc. (NASDAQ: MDNU) today announced that it has been issued a patent for its Pro-Stat® line of products for treating wounds to promote healing (U.S. Patent No. 7,318,934). Pro-Stat®, which is used in approximately 5,000 nursing homes, hospitals and dialysis clinics, provides nitrogen-rich, hydrolyzed protein and calories in concentrated liquid form. Pro-Stat® has been shown to be an effective nutritional intervention to aid in the treatment of pressure ulcers, protein energy malnutrition, recent weight loss, hypoalbuminemia, and end stage renal disease patients undergoing hemodialysis. In its March 2006 issue, the Journal of Advances in Skin and Wound Care reported a clinical trial showing patients given Pro-Stat® in addition to standard care had a 96% greater healing rate for Stage II, III, and IV pressure ulcers (bed sores) than patients who received standard care alone.

"This patent further validates the improved clinical outcomes resulting from the use of Pro-Stat® in promoting the healing of wounds," said Frank A. Newman, Chairman and Chief Executive Officer.

About Medical Nutrition USA

Medical Nutrition USA develops and distributes products for the nutritionally at risk who are under medical supervision. Its products are used primarily in long-term care facilities, hospitals, dialysis clinics and bariatric clinics. The Company's product lines include Pro-Stat®, Fiber-Stat®, as well as private label products. Additional information is available at www.mdnu.com.

Contact Information

  • Contacts:
    Medical Nutrition USA, Inc.
    Alan Levy
    Vice President/Finance
    Chief Financial Officer
    800-221-0308
    Email Contact

    Investor Relations Counsel
    The Equity Group Inc.
    Linda Latman, 212-836-9609
    Lena Cati, 212-836-9611
    Email Contact
    www.theequitygroup.com